During the past decade, Beijing Cancer Hospital conducted 621 clinical trials. In the 10-year time frame, 621 clinical trials started and 65 clinical trials were completed, i.e. on average, 10.5% percent of trials that started reached the finish line to date. In the past 5 years, 365 clinical trials started and 47 clinical trials were completed. i.e. 12.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Beijing Cancer Hospital" #1 sponsor was "Peking University Cancer Hospital & Institute" with 84 trials, followed by "Peking University" with 62 trials sponsored, "Hoffmann-La Roche" with 57 trials sponsored, "BeiGene" with 39 trials sponsored and "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 39 trials sponsored. Other sponsors include 420 different institutions and companies that sponsored additional 184 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Beijing Cancer Hospital" #1 collaborator was "Peking University Cancer Hospital & Institute" with 32 trials as a collaborator, "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 12 trials as a collaborator, "Chinese PLA General Hospital" with 9 trials as a collaborator, "Peking Union Medical College Hospital" with 9 trials as a collaborator and "Peking University People's Hospital" with 9 trials as a collaborator. Other collaborators include 342 different institutions and companies that were collaborators in the rest 221 trials.

According to Clinical.Site data, the most researched conditions in "Beijing Cancer Hospital" are "Gastric Cancer" (39 trials), "Melanoma" (27 trials), "Breast Cancer" (25 trials), "Non-small Cell Lung Cancer" (23 trials) and "Solid Tumor" (23 trials). Many other conditions were trialed in "Beijing Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Beijing Cancer Hospital" are "Drug" (588 trials), "Biological" (76 trials), "Other" (30 trials), "Procedure" (28 trials) and "Radiation" (28 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (62 trials), "Cisplatin" (41 trials), "Paclitaxel" (31 trials), "Carboplatin" (29 trials) and "Tislelizumab" (29 trials). Other intervention names were less common.

The vast majority of trials in "Beijing Cancer Hospital" are 631 trials for "All" genders, 53 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are 379 active trials in "Beijing Cancer Hospital". 29 are not yet recruiting, 208 are recruiting, 135 are Active, not recruiting, and 7 are Enrolling by invitation. In total, there were 128 completed trials in Beijing Cancer Hospital, undefined suspended trials, and 24 terminated clinical trials to date.

Out of the total trials that were conducted in Beijing Cancer Hospital, 183 "Phase 1" clinical trials were conducted, 249 "Phase 2" clinical trials and 223 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 15 trials, and there were also 37 trials that are defined as “Not Applicable".

Beijing Cancer Hospital has several departments that took part in Clinical trials: "Peking University Cancer Hospital" - 156 trials